Vidac Pharma Holding Plc | WebDisclosure

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Headlines Articles Press releases Vidac Pharma Holding Plc

Home
Companies
Vidac Pharma Holding Plc

BRIEF

published on 11/20/2025 at 16:29, 14 days 14 hours ago

Vidac Pharma Holding Plc obtient l'autorisation de mener des essais cliniques

Essai Clinique Vidac Pharma Conseils En Investissement Agence Européenne Des Médicaments Kératoses Actiniques
BRIEF

published on 11/20/2025 at 16:29, 14 days 14 hours ago

Vidac Pharma Holding Plc Granted Authorization for Clinical Trials

Clinical Trial Investment Advice Vidac Pharma European Medicines Agency Actinic Keratoses
PRESS RELEASE

published on 11/20/2025 at 16:24, 14 days 14 hours ago

Original-Research: Vidac Pharma Holding Plc (von Sphene Capital GmbH): Buy
Vidac Pharma Holding Plc receives EMA approval for clinical trial on actinic keratoses, advancing towards pivotal studies. Sphene Capital upgrades target price to EUR 4.20

Target Price Clinical Trial Sphene Capital Vidac Pharma EMA Approval
BRIEF

published on 08/22/2025 at 05:41, 3 months 14 days ago

L'approche de Vidac Pharma Holding Plc renforcée par une nouvelle étude

Traitement Du Cancer Vidac Pharma Transplantation Mitochondriale Effet Warburg Objectif De Cours : 4,30 EUR
BRIEF

published on 08/22/2025 at 05:41, 3 months 14 days ago

Vidac Pharma Holding Plc's Approach Bolstered by New Study

Cancer Treatment Vidac Pharma Mitochondrial Transplantation Warburg Effect Target Price EUR 4.30
PRESS RELEASE

published on 08/22/2025 at 05:36, 3 months 14 days ago

Original-Research: Vidac Pharma Holding Plc (von Sphene Capital GmbH): Buy
Research analysis reveals the effectiveness of mitochondrial transplantation in increasing tumour cell sensitivity to chemotherapy, confirming Vidac Pharma's innovative approach. Buy recommendation maintained for Vidac Pharma

Buy Recommendation Vidac Pharma Mitochondrial Transplantation Chemotherapy Sensitivity Research Analysis
BRIEF

published on 06/24/2025 at 13:52, 5 months 10 days ago

Vidac Pharma's Promising Pediatric Cancer Data

Investment Recommendation Vidac Pharma Pediatric Cancer Almavid VDA 1102
BRIEF

published on 06/24/2025 at 13:52, 5 months 10 days ago

Données prometteuses de Vidac Pharma sur le cancer pédiatrique

Recommandation D'investissement Vidac Pharma Cancer Pédiatrique Almavid VDA 1102
PRESS RELEASE

published on 06/24/2025 at 13:47, 5 months 10 days ago

Original-Research: Vidac Pharma Holding Plc (von Sphene Capital GmbH): Buy
Vidac Pharma Holding Plc assessment and promising data in paediatric brain cancer patients presented by Sphene Capital GmbH. Equity value analysis using DCF model

Sphene Capital GmbH Vidac Pharma DCF Model Paediatric Brain Cancer Equity Value Analysis
BRIEF

published on 11/20/2024 at 09:21, 1 year ago

Vidac Pharma obtient un brevet clé de l'USPTO

Essais Cliniques Traitement Du Cancer Brevet USPTO Vidac Pharma Hexokinase-2

Accesswire

Published on 12/05/2025 at 02:35, 4 hours 5 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 4 hours 10 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 5 hours 40 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 35 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 40 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 3 hours 10 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 50 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 15 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 25 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 30 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:14, 12 hours 26 minutes ago

Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 12 hours 40 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 12 hours 40 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 55 minutes ago

Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 12 hours 55 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE